Berinert

BIOLOGICAL4 trials

Sponsors

CSL Behring, Technical University of Munich, Cedars-Sinai Medical Center, National Institute of Allergy and Infectious Diseases (NIAID)

Conditions

Acute ACE-induced AngioedemaChronic Kidney DiseasesEnd Stage Renal DiseaseHereditary Angioedema Types I and IIKidney Transplant

Phase 1

A Study to Evaluate the Safety and Pharmacokinetics of Two Formulations of C1-esterase Inhibitor

CompletedNCT01760343

CSL BehringHereditary Angioedema Types I and II

Start: 2013-01-31End: 2013-03-31Updated: 2013-04-05

Berinert (C1INH) vs Placebo for DGF/IRI

CompletedNCT04696146

Cedars-Sinai Medical CenterChronic Kidney Diseases, End Stage Renal Disease

Start: 2021-03-03End: 2024-10-31Updated: 2024-12-04

Phase 2

Improving Deceased-Donor Kidney Transplant Outcomes Via a Single Intragraft Injection of C1 Esterase Inhibitor (IMPROVE TRIAL)

RecruitingNCT06919003

National Institute of Allergy and Infectious Diseases (NIAID)Kidney Transplant

Start: 2025-09-22End: 2032-05-30Target: 180Updated: 2026-02-27

Phase 3

Randomized, Double-blind, Two Arms, Multicenter, Phase III Study of Berinert for Treatment of ACE Induced Angioedema

CompletedNCT01843530

Technical University of MunichAcute ACE-induced Angioedema

Start: 2013-11-30End: 2019-09-30Updated: 2023-11-24

Related Papers

Back-table intra-arterial administration of C1 esterase inhibitor to deceased donor kidney allografts improves posttransplant allograft function: Results of a randomized double-blind placebo-controlled clinical trial.

2025-05-093 citations